Abstract

Licorice-induced pseudoaldosteronism is a common adverse effect in traditional Japanese Kampo medicine, and 3-monoglucuronyl glycyrrhetinic acid (3MGA) was considered as a causative agent of it. Previously, we found 22α-hydroxy-18β-glycyrrhetyl-3-O-sulfate-30-glucuronide (1), one of the metabolites of glycyrrhizin (GL) in the urine of Eisai hyperbilirubinuria rats (EHBRs) treated with glycyrrhetinic acid (GA), and suggested that it is also a possible causative agent of pseudoaldosteronism. The discovery of 1 also suggested that there might be other metabolites of GA as causal candidates. In this study, we found 22α-hydroxy-18β-glycyrrhetyl-3-O-sulfate (2) and 18β-glycyrrhetyl-3-O-sulfate (3) in EHBRs’ urine. 2 and 3 more strongly inhibited rat type 2 11β-hydroxysteroid dehydrogenase than 1 did in vitro. When EHBRs were orally treated with GA, GA and 13 in plasma and 13 in urine were detected; the levels of 3MGA were quite low. 2 and 3 were shown to be the substrates of organic anion transporter (OAT) 1 and OAT3. In the plasma of a patient suffering from pseudoaldosteronism with rhabdomyolysis due to licorice, we found 8.6 µM of 3, 1.3 µM of GA, and 87 nM of 2, but 1, GL, and 3MGA were not detected. These findings suggest that 18β-glycyrrhetyl-3-O-sulfate (3) is an alternative causative agent of pseudoaldosteronism, rather than 3MGA and 1.

Details

Title
18β-glycyrrhetyl-3-O-sulfate would be a causative agent of licorice-induced pseudoaldosteronism
Author
Ishiuchi Kan’ichiro 1   VIAFID ORCID Logo  ; Morinaga Osamu 2 ; Ohkita Takeshi 1 ; Tian Chuanting 1 ; Hirasawa Asuka 1 ; Mitamura Miaki 1 ; Maki Yasuhito 1 ; Kondo Tsubasa 2 ; Yasujima Tomoya 3 ; Yuasa Hiroaki 3 ; Minamizawa Kiyoshi 4 ; Namiki Takao 5 ; Makino Toshiaki 1   VIAFID ORCID Logo 

 Nagoya City University, Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Mizuho-ku, Japan (GRID:grid.260433.0) (ISNI:0000 0001 0728 1069) 
 Daiichi University of Pharmacy, Department of Natural Medicines, Minami-ku, Japan (GRID:grid.417740.1) (ISNI:0000 0004 0370 1830) 
 Nagoya City University, Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Mizuho-ku, Japan (GRID:grid.260433.0) (ISNI:0000 0001 0728 1069) 
 Kameda Medical Center, Department of Oriental Medicine, Kamogawa, Japan (GRID:grid.414927.d) (ISNI:0000 0004 0378 2140) 
 Chiba University Hospital, Department of Japanese-Oriental (Kampo) Medicine, Chiba-shi, Japan (GRID:grid.411321.4) (ISNI:0000 0004 0632 2959) 
Publication year
2019
Publication date
Dec 2019
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2176710278
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.